Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.39 |
| ▸ | RORC | P51449 | 1/20 | 0.38 |
| ▸ | STS | P08842 | 3/20 | 0.37 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.37 |
| ▸ | MC4R | P32245 | 3/20 | 0.37 |
| ▸ | MC5R | P33032 | 2/20 | 0.37 |
| ▸ | MC3R | P41968 | 2/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.37 |
| ▸ | MC1R | Q01726 | 1/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.36 |
| ▸ | CNR1 | P21554 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31734969 | 0.87 | USP30 (0.49) | USP30MEN1KMT2APDK2STS | |
| SCHEMBL31734975 | 0.85 | USP30 (0.41) | USP30MEN1KMT2APDK2STS | |
| SCHEMBL31735059 | 0.83 | ANO1 (0.41) | USP30MEN1KMT2ASTSESR2 | |
| SCHEMBL31734907 | 0.79 | MEN1 (0.48) | USP30MEN1KMT2ARORCSTS | |
| SCHEMBL653102 | 0.79 | MEN1 (0.48) | USP30MEN1KMT2ARORCSTS | |
| SCHEMBL30674339 | 0.78 | USP30 (0.47) | USP30MEN1KMT2APDK2RORC | |
| SCHEMBL31735070 | 0.76 | USP30 (0.45) | USP30MEN1KMT2AGPR119STS | |
| SCHEMBL31734953 | 0.76 | SSTR4 (0.38) | MEN1KMT2APDK2GPR119RORC | |
| SCHEMBL31734864 | 0.74 | USP30 (0.46) | USP30PDK2GPR119RORCMC4R | |
| SCHEMBL31735094 | 0.74 | RAB9A (0.42) | PDK2CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250361230-A1 | LATS Inhibitors and Uses Thereof | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2025-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250361230-A1 | LATS Inhibitors and Uses Thereof | LATS2, LATS1, AKT1S1 | USP30 3692/4885MEN1 3854/4885KMT2A 3560/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.